Anteris Technologies Global (NASDAQ:AVR) Major Shareholder L1 Capital Pty Ltd Sells 251,844 Shares

Anteris Technologies Global Corp. (NASDAQ:AVR) major shareholder L1 Capital Pty Ltd sold 251,844 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $9.10, for a total transaction of $2,291,780.40. Following the sale, the insider directly owned 5,187,156 shares of the company’s stock, valued at $47,203,119.60. This represents a 4.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

L1 Capital Pty Ltd also recently made the following trade(s):

• On Tuesday, August 11th, L1 Capital Pty Ltd sold 375,815 shares of Anteris Technologies Global stock. The stock was sold at an average price of $9.30, for a total transaction of $3,495,079.50.
• On Thursday, August 6th, L1 Capital Pty Ltd sold 174,721 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.10, for a total transaction of $1,415,240.10.
• On Tuesday, August 4th, L1 Capital Pty Ltd sold 480,608 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.30, for a total transaction of $3,989,046.40.
• On Wednesday, August 5th, L1 Capital Pty Ltd sold 14,581 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.23, for a total transaction of $120,001.63.
• On Monday, August 3rd, L1 Capital Pty Ltd sold 475,693 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.10, for a total transaction of $3,853,113.30.
• On Friday, July 31st, L1 Capital Pty Ltd sold 48,711 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.15, for a total transaction of $396,994.65.
• On Wednesday, July 29th, L1 Capital Pty Ltd sold 155,505 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.04, for a total transaction of $1,250,260.20.
• On Thursday, July 30th, L1 Capital Pty Ltd sold 558,633 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.20, for a total value of $4,580,790.60.
• On Monday, July 27th, L1 Capital Pty Ltd sold 232,817 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.19, for a total value of $1,906,771.23.
• On Tuesday, July 28th, L1 Capital Pty Ltd sold 208,731 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.09, for a total value of $1,688,633.79.

Anteris Technologies Global Price Performance

Shares of Anteris Technologies Global stock opened at $9.17 on Wednesday. The stock’s 50-day moving average is $9.15 and its 200 day moving average is $7.33. Anteris Technologies Global Corp. has a one year low of $3.17 and a one year high of $11.06. The firm has a market cap of $892.61 million, a price-to-earnings ratio of -4.11 and a beta of 1.78.

Anteris Technologies Global (NASDAQ:AVR) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.09). Anteris Technologies Global had a negative net margin of 5,148.78% and a negative return on equity of 124.76%. The company had revenue of $1.01 million during the quarter, compared to the consensus estimate of $1.50 million. During the same quarter in the prior year, the firm earned ($0.58) EPS. On average, sell-side analysts expect that Anteris Technologies Global Corp. will post -1.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Anteris Technologies Global

Hedge funds and other institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Anteris Technologies Global during the 1st quarter valued at about $32,000. Geode Capital Management LLC increased its holdings in Anteris Technologies Global by 154.3% during the 2nd quarter. Geode Capital Management LLC now owns 420,427 shares of the company’s stock worth $1,593,000 after purchasing an additional 255,088 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Anteris Technologies Global by 9,958.6% in the second quarter. JPMorgan Chase & Co. now owns 1,068,328 shares of the company’s stock worth $4,049,000 after purchasing an additional 1,057,707 shares during the last quarter. Nantahala Capital Management LLC raised its stake in shares of Anteris Technologies Global by 1.8% in the second quarter. Nantahala Capital Management LLC now owns 1,693,666 shares of the company’s stock worth $6,419,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Anteris Technologies Global by 85.1% in the third quarter. Vanguard Group Inc. now owns 745,560 shares of the company’s stock valued at $3,355,000 after purchasing an additional 342,711 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Anteris Technologies Global from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Barclays raised their target price on Anteris Technologies Global from $17.00 to $18.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anteris Technologies Global in a research note on Friday, May 29th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Anteris Technologies Global presently has an average rating of “Moderate Buy” and a consensus target price of $16.00.

About Anteris Technologies Global

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.